NASDAQ:MNKD

MannKind Stock Forecast, Price & News

$4.18
-0.12 (-2.79 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.12
Now: $4.18
$4.31
50-Day Range
$3.21
MA: $4.03
$5.71
52-Week Range
$1.14
Now: $4.18
$6.25
Volume2.78 million shs
Average Volume5.84 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.28
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. The company offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity used for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of Treprostinil (Tyvaso DPI) used for the treatment of pulmonary arterial hypertension. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MannKind logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MNKD
CUSIP56400P20
Phone818-661-5000
Employees240
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.04 million
Book Value($0.92) per share

Profitability

Net Income$-51,900,000.00

Miscellaneous

Market Cap$1.04 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableOptionable

Headlines

MannKind Co. (NASDAQ:MNKD) Sees Large Increase in Short Interest
April 18, 2021 |  americanbankingnews.com
MNKD Apr 2021 2.000 call
April 12, 2021 |  finance.yahoo.com
MannKind (NASDAQ:MNKD) Stock Price Up 8.7%
April 1, 2021 |  americanbankingnews.com
MannKind Co. (NASDAQ:MNKD) Short Interest Up 68.2% in March
March 30, 2021 |  americanbankingnews.com
MNKD Apr 2021 7.500 put
March 29, 2021 |  au.finance.yahoo.com
MannKind (NASDAQ:MNKD) Trading Up 3.7%
March 25, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

617th out of 2,024 stocks

Pharmaceutical Preparations Industry

285th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$4.18
-0.12 (-2.79 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MannKind (NASDAQ:MNKD) Frequently Asked Questions

Is MannKind a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MannKind stock.
View analyst ratings for MannKind
or view top-rated stocks.

What stocks does MarketBeat like better than MannKind?

Wall Street analysts have given MannKind a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MannKind wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting MannKind?

MannKind saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 38,610,000 shares, an increase of 34.1% from the March 15th total of 28,800,000 shares. Based on an average daily trading volume, of 6,010,000 shares, the days-to-cover ratio is presently 6.4 days.
View MannKind's Short Interest
.

When is MannKind's next earnings date?

MannKind is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for MannKind
.

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.03. The biopharmaceutical company had revenue of $18.44 million for the quarter, compared to analysts' expectations of $16.13 million.
View MannKind's earnings history
.

How has MannKind's stock price been impacted by Coronavirus (COVID-19)?

MannKind's stock was trading at $1.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MNKD stock has increased by 280.0% and is now trading at $4.18.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MNKD?

5 analysts have issued 12 month price objectives for MannKind's stock. Their forecasts range from $5.00 to $8.00. On average, they expect MannKind's stock price to reach $6.63 in the next twelve months. This suggests a possible upside of 58.5% from the stock's current price.
View analysts' price targets for MannKind
or view top-rated stocks among Wall Street analysts.

Who are MannKind's key executives?

MannKind's management team includes the following people:
  • Dr. Michael E. Castagna, CEO & Director (Age 44, Pay $844.2k)
  • Mr. Steven B. Binder, Chief Financial Officer (Age 58, Pay $630.4k)
  • Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 54, Pay $675.97k)
  • Mr. James Patrick McCauley Jr., J.D., M.B.A., Chief Commercial Officer (Age 55, Pay $614.06k)
  • Mr. Joseph Kocinsky, Chief Technology Officer (Age 57)
  • Ms. Rosabel Realica Alinaya, VP of Investor Relations & Treasury (Age 60)
  • Dr. Stuart A. Tross, Chief People & Workplace Officer (Age 54)
  • Mr. John F. Bedard, Sr. VP of Worldwide Regulatory Affairs (Age 71)
  • Mr. Alejandro Galindo M.B.A., M.S., Chief Commercial Officer (Age 49)

Who are some of MannKind's key competitors?

What other stocks do shareholders of MannKind own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MannKind investors own include Bausch Health Companies (BHC), Novavax (NVAX), Geron (GERN), ACADIA Pharmaceuticals (ACAD), Advanced Micro Devices (AMD), Chesapeake Energy (CHKAQ), Micron Technology (MU), NVIDIA (NVDA), Intel (INTC) and Gilead Sciences (GILD).

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

Who are MannKind's major shareholders?

MannKind's stock is owned by a number of retail and institutional investors. Top institutional investors include Pacer Advisors Inc. (0.01%), WealthTrust Axiom LLC (0.00%) and Global Retirement Partners LLC (0.00%). Company insiders that own MannKind stock include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder and Stuart A Tross.
View institutional ownership trends for MannKind
.

Which institutional investors are selling MannKind stock?

MNKD stock was sold by a variety of institutional investors in the last quarter, including Global Retirement Partners LLC.
View insider buying and selling activity for MannKind
or view top insider-selling stocks.

Which institutional investors are buying MannKind stock?

MNKD stock was acquired by a variety of institutional investors in the last quarter, including WealthTrust Axiom LLC, and Pacer Advisors Inc.. Company insiders that have bought MannKind stock in the last two years include Alejandro Galindo, Michael Castagna, Patrick Mccauley, Roxanne S Austin, Steven B Binder, and Stuart A Tross.
View insider buying and selling activity for MannKind
or or view top insider-buying stocks.

How do I buy shares of MannKind?

Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MannKind's stock price today?

One share of MNKD stock can currently be purchased for approximately $4.18.

How much money does MannKind make?

MannKind has a market capitalization of $1.04 billion and generates $63.04 million in revenue each year. The biopharmaceutical company earns $-51,900,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does MannKind have?

MannKind employs 240 workers across the globe.

What is MannKind's official website?

The official website for MannKind is www.mannkindcorp.com.

Where are MannKind's headquarters?

MannKind is headquartered at 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362.

How can I contact MannKind?

MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.